Traveler's Diarrhea

ProdiGene, NIH begin study on oral vaccine derived from transgenic corn

Published in Vaccine Weekly, September 18th, 2002

ProdiGene, Inc., announced that it will begin a phase I clinical trial in cooperation with the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID), studying the safety and immunogenicity of an oral vaccine against Traveler's Diarrhea, a condition caused by Enterotoxigenic E. coli (ETEC).

This vaccine is produced using ProdiGene's proprietary transgenic plant technology and delivered using the company's patented oral vaccine platform.

Under the agreement, NIAID will fund the trial and ProdiGene will supply the corn vaccine. In addition to funding the trial, NIAID will manage the trial and sponsor...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-09-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry